does the va cover glp-1 Paving way for expanded coverage | Insights & Events GLP1 Receptor Agonists vs SGLT2-I

The market is being reshaped by 6 forces: Market size: $94B today $216B+ by 2035 (8.8% CAGR) Oral GLP-1s just got FDA approval eliminating the needle barrier for millions WHO officially recommends GLP-1s for long-term obesity treatment (Dec 2025) Novo Nordisk slashed Ozempic/Wegovy prices by up to 70% unlocking mass adoption Next-gen tri-agonists (retatrutide) showing 28.7% weight loss in trials Only ~7% diabetes penetration and ~2% obesity penetration the growth runway is massive The ripple effects extend far beyond pharma: Food & beverage: $30$55B annual revenue at risk as GLP-1 users cut calories by 21% Employers: 77% of large companies say managing GLP-1 costs is a top priority Eli Lilly became the first pharma company to surpass $1 trillion market cap ~150 GLP-1 drugs now in development globally 2530 million Americans projected on GLP-1 therapy by 2030 The question isnt whether GLP-1s will reshape global healthcare

The mechanisms of both subacute and idiosyncratic VHT remain incompletely understood, but it has been believed since the early 1980s based on limited experimental and clinical evidence [5356] that hypocarnitinaemia, subsequent imbalance between -oxidation and -oxidation, and accumulation of 4-en-VPA are involved

Reported effects are generally mild and may include injection-site reactions (redness, soreness, swelling), nausea, stomach upset, headache, or fatigue

Deciphering HER2 breast cancer disease: Biological and clinical implications